Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
Phone888-720-4450
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.49 billion
Profitability
Miscellaneous
Employees2,419
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable
Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions
What is Diplomat Pharmacy's stock symbol?
Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."
How were Diplomat Pharmacy's earnings last quarter?
Diplomat Pharmacy Inc (NYSE:DPLO) issued its quarterly earnings results on Friday, March, 15th. The company reported $0.14 EPS for the quarter, missing the Zacks' consensus estimate of $0.24 by $0.10. The firm had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.41 billion. Diplomat Pharmacy had a positive return on equity of 5.51% and a negative net margin of 5.50%. The business's revenue was up 17.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.09 EPS. View Diplomat Pharmacy's Earnings History.
When is Diplomat Pharmacy's next earnings date?
What guidance has Diplomat Pharmacy issued on next quarter's earnings?
Diplomat Pharmacy updated its FY19 earnings guidance on Friday, March, 15th. The company provided earnings per share guidance of ($0.50-0.34) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.18). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $5.51 billion.Diplomat Pharmacy also updated its FY 2019 guidance to $-0.5-0.34 EPS.
What price target have analysts set for DPLO?
11 brokers have issued twelve-month price targets for Diplomat Pharmacy's shares. Their forecasts range from $6.00 to $30.00. On average, they expect Diplomat Pharmacy's share price to reach $11.10 in the next year. This suggests a possible upside of 85.9% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.
What is the consensus analysts' recommendation for Diplomat Pharmacy?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.
Has Diplomat Pharmacy been receiving favorable news coverage?
News headlines about DPLO stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Diplomat Pharmacy earned a news sentiment score of 2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
Who are some of Diplomat Pharmacy's key competitors?
What other stocks do shareholders of Diplomat Pharmacy own?
Who are Diplomat Pharmacy's key executives?
Diplomat Pharmacy's management team includes the folowing people:
- Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
- Mr. Atul Kavthekar, CFO & Treasurer
- Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 61)
- Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
- Mr. Dave Loschinskey, Chief Information Officer
Who are Diplomat Pharmacy's major shareholders?
Diplomat Pharmacy's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.62%), Dimensional Fund Advisors LP (2.86%), Dimensional Fund Advisors LP (2.86%), Bank of New York Mellon Corp (2.26%), Northern Trust Corp (1.73%) and Rhenman & Partners Asset Management AB (1.62%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.
Which institutional investors are selling Diplomat Pharmacy stock?
DPLO stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, D. E. Shaw & Co. Inc., Bank of America Corp DE, Empirical Capital Management LLC, GW&K Investment Management LLC, Mackay Shields LLC, Barclays PLC and MetLife Investment Advisors LLC. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Jeffrey G Park, Philip R Hagerman and Shawn Tomasello. View Insider Buying and Selling for Diplomat Pharmacy.
Which institutional investors are buying Diplomat Pharmacy stock?
DPLO stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Advisory Services Network LLC, FMR LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Royce & Associates LP, Norges Bank and BlackRock Inc.. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.
How do I buy shares of Diplomat Pharmacy?
Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Diplomat Pharmacy's stock price today?
One share of DPLO stock can currently be purchased for approximately $5.97.
How big of a company is Diplomat Pharmacy?
Diplomat Pharmacy has a market capitalization of $444.71 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.
What is Diplomat Pharmacy's official website?
How can I contact Diplomat Pharmacy?
Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]
MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
